News Center

Home page

Peak Report

News reports

Azithromycin Sulfate for Injection Instructions

Release time:

2020-07-31

Approval Date: March 29, 2007
First Amendment Date: November 13, 2007
Second Amendment Date: October 31, 2014

-dimensional Ruth
Azithromycin Sulfate Instructions
Please read the instructions carefully and use them under the guidance of doctors.

[Drug Name]
Common Name: Azithromycin Sulfate for Injection
Trade Name: Verude
English Name: Azithromycin Sulfate for Injection
Chinese Pinyin: ZhusheyongLiusuan Aqimeisu
[Ingredients] The main ingredient of this product is azithromycin sulfate, and its chemical name is: 9-deoxy -9 α-aza -9 α-methyl -9 α-erythromycin A sulfate.
Chemical Structural Formula:

Molecular Formula: C38H72N2012 H2S04
Molecular Weight: 847.00
[Character] This product is white or almost white loose block or powder.
[indications] 1, for acute pharyngitis caused by Streptococcus pyogenes, acute tonsillitis.
2. For pneumonia caused by Streptococcus pneumoniae, influenza bacillus and Mycoplasma pneumoniae.
3, for chlamydia caused by urethritis and cervicitis.
4. It is used for acute bronchitis and acute attack of chronic bronchitis caused by sensitive bacteria.
5. For skin and soft tissue infections caused by sensitive bacteria.
[Specifications] 0.25g (250000 units) and 0.5g (500000 units) (calculated by C38H72N2012)

[Usage and Dosage] Fully dissolve the product with appropriate amount of water for injection to prepare a solution containing 0.1g per 1ml, then add it to 250ml or 500ml of 0.9 sodium chloride injection or 5% glucose injection, and the final azithromycin concentration is 1.0-2.0 mg/ml for intravenous drip, instillation time: 1 mg/ml, instillation for 3 hours; 2 mg/ml, instillation for 1 hour. For the treatment of community-acquired pneumonia, the adult dosage is 0.5g each time, once a day, for at least 2 consecutive days. Next, azithromycin oral preparation 0.5g/day, 7-10 days of treatment for a course of treatment. The timing of conversion to oral therapy should be determined by the physician based on clinical response. For the treatment of pelvic inflammatory disease, the adult dosage is 0.5g each time, once a day. After 1 day or 2 days of medication, azithromycin oral preparation O.25g is used instead, with 7 days as a course of treatment. The timing of conversion to oral therapy should be determined by the physician based on clinical response. If an anaerobic infection is suspected, an anti-anaerobic drug should be used.
[adverse reactions] occasionally can appear dizziness, headache and fever, rash, joint pain and other allergic reactions, rare anaphylactic shock and angioedema. A few patients may have transient neutropenia and elevated serum aminotransferase.
[taboo] to erythromycin or other macrolide drug allergy is prohibited.
[Precautions] Patients with liver damage should use this product with caution.
[medication for pregnant and lactating women] animal experiments have shown that azithromycin has no effect on the fetus, but it is still lack of experience in the application of human pregnant women, so it is necessary to fully weigh the pros and cons in the application of pregnant women.
There is no information on whether azithromycin can be secreted into breast milk, and the use of azithromycin in lactating women should be considered with caution.
[Children's medication] The dosage and administration method for children under 6 months of age have not been established. Efficacy and safety for the treatment of otitis media in infants less than 6 months of age, community-acquired pneumonia, and pharyngitis or tonsillitis in children less than 2 years of age have not been established.
[Geriatric use] This experiment has not been performed and there are no reliable references.
[Drug Interactions] l. When combined with aminophylline, attention should be paid to monitoring the blood concentration of the latter.
2, and warfarin should pay attention to check the prothrombin time.
3, combined with carbamazepine and digoxin, can increase the blood concentration of carbamazepine and digoxin.
[Overdose] This experiment was not performed and there are no reliable references.
[Pharmacology and Toxicology] Azithromycin is a 15-member ring macrolide, the first variety of nitrogen lactones. Its mechanism of action is the same as that of erythromycin, which mainly binds to the 50s subunit of bacterial ribosome and inhibits RNA-dependent protein synthesis. This product has good antibacterial effect on Streptococcus pyogenes, Streptococcus pneumoniae and influenza bacillus, and also has antibacterial activity on Staphylococcus. This product on Staphylococcus, Streptococcus and other Gram-positive cocci antibacterial effect is slightly worse than erythromycin on influenza bacilli and Moraxella catarrh antibacterial effect than erythromycin 4~8 times and 2~4 times, on a small number of Escherichia coli, Salmonella, Shigella can also have antibacterial effect. This product has good antimicrobial effect on anaerobic bacteria such as digestive streptococcus, mycoplasma pneumoniae and chlamydia trachomatis.
[Pharmacokinetics] This product is widely distributed in the body, and its concentration in various tissues can reach l0 ~ 100 times of the blood drug concentration in the same period. This product has high concentration in macrophages and fibroblasts, the former can transport azithromycin to the site of inflammation. The half-life (tl/2) of azithromycin after a single dose is 35-48 hours, more than 50% of the dose is excreted through the biliary tract in the original form, and about 4.5 within 72 hours after administration is excreted in the original form with urine.
[Storage] Closed and stored in a cool place (not more than 20 ℃).
[Packaging] Glass bottles, 0.25g × 2 bottles/box, 0.25g × 1 bottle/box, 0.25g × 10 bottles/box, 0.5g × 1 bottle/box, 0.5g × 10 bottles/box.
[validity] tentatively 24 months.
[Implementation Standard] WS-359(X-305)-2002(1)(0.25g);WS-359(X-305)-2002(2)(0.5g)
[Approval Document No.] H20000728(0.25g), H20000729(0.5g).
[Production Enterprise]
Enterprise Name: Zhejiang Jianfeng Pharmaceutical Co., Ltd.
Address: No. 58, Gaofan Section, Baitang Downline, Wucheng District, Jinhua City, Zhejiang Province
Tel: 0579-82661998 (Consultation) 0579-82131973 (Sales)
Fax Number: 0579-82661998 Postal Code: 321075
Website: www.zjjfyy.com.cn

More information

Inferior spikes do this

In the eastern corner of the production area of Jianfeng Health Technology Company, there is a very inconspicuous building. From below, only a few pipes of uneven thickness can be seen on the top and the slogan "Focus on Environmental Protection and Promote Sustainable Development" with red letters on the yellow background on the stainless steel guardrail. Walking up, you can only see several closed pools and a small room with stacks of documents, test tubes, glass bottles and other testing tools on the table. This is the peak and healthy sewage treatment station. The production sewage of the whole factory area is concentrated here. After adjustment (PH adjustment), pre-acidification, anaerobic, anoxic, aerobic (aeration), precipitation and other links, it is discharged into the pipe network after reaching the special discharge standard. Yin Zhiwu, executive deputy general manager of Jianfeng Health, said that because the sewage treatment station in Wucheng District has not yet been built, Jianfeng Health has not yet been able to achieve pipe discharge, and the relevant national laws have strict requirements on the discharge of water pollutants from the extraction pharmaceutical industry. Sewage discharge must reach a special discharge limit, that is, chemical oxygen demand (COD) must be less than 50 mg/L. Enterprise development and environmental protection are both the concept of peak health since its establishment. In March this year, on the basis of the original environmental protection facilities, Jianfeng Health carried out technical renovation of waste gas collection and treatment facilities, and at the same time installed a sealing cover on the sewage treatment station to realize the closed collection of waste gas. Since the trial operation of this facility in mid-May, the overall effect has been obvious. The original treatment tank would emit an unpleasant smell during work, but now the smell has been significantly reduced. Compared with the young enterprise of peak health, the relatively "older" peak pharmaceutical has more experience in sewage treatment and environmental protection. Akihama

2020

07-31

2016 Annual General Meeting of Shareholders

News from our newspaper On May 19, the on-site meeting of Jianfeng Group's 2016 Annual General Meeting of Shareholders was held in Conference Room 314 of Jianfeng Building to deliberate and pass the "2016 Annual Report on the Work of the Board of Directors" and other proposals. The meeting was convened by the board of directors of Jianfeng Group and chaired by Chairman Jiang Xiaomeng. A total of 6 shareholders and proxies attended the meeting, and the total number of voting shares held by them was 55,604,815, accounting for 16.16 of the total voting shares of the company. Some directors, supervisors and secretary of the board of directors of the company attended the meeting, and some senior managers attended the meeting as nonvoting delegates. The meeting was held and voted on by a combination of on-site voting and online voting, it deliberated and passed nine proposals, including the 2016 Work Report of the Board of Directors, the 2016 Work Report of the Board of Supervisors, the 2016 Financial Final Accounts Report, the 2016 Profit Distribution Proposal, the Proposal to Hire the Company's 2017 Audit Institution, the Proposal to Provide Guarantee to Holding Subsidiaries, the 2016 Annual Report and its Summary, the Election of Mr. Huang Sujian as Director of the Company and the Election of Mr. Chen Tianci as Supervisor of the Company. (Zhou Hengbin)

2020

07-31

2016 Annual General Meeting of Shareholders

2020

07-31

2016 Annual General Meeting of Shareholders

2020

07-30

Jianfeng Pharmaceutical Won Advanced Collective of Municipal Red Cross Humanitarian Promotion Award

On April 24, the Red Cross Society of Jinhua issued a circular commending the advanced units and individuals of the 2016 Red Cross Humanitarian Promotion Award. Peak Pharmaceutical Company won the Red Cross Humanitarian Promotion Award for Advanced Collective. The Red Cross is a social relief organization engaged in humanitarian work, with the purpose of carrying forward the spirit of humanity, fraternity and dedication, protecting human life and health, and promoting the cause of peace and progress of mankind. As a socially responsible enterprise, Jianfeng Pharmaceutical has always attached importance to public welfare and charity work, vigorously promoted the spirit of the Red Cross, and vigorously supported the work of the Red Cross with practical actions. In September 2016, at the theme publicity activity of "World First Aid Day" and the opening ceremony of the municipal Red Cross emergency rescue station (point), Huang Jinlong, deputy general manager of the group company and general manager of the pharmaceutical company, donated 6 AEDs known as "life-saving artifact" to the Red Cross on behalf of Jianfeng Pharmaceutical, it is equipped with six Red Cross emergency rescue service stations (points), namely, Jinhua high-speed railway station, sports center, cultural center, Shuanglong scenic spot, Siping village scenic spot and Suoyuan village scenic spot. The configuration of AED equipment has played a very good role in improving the emergency rescue capacity of Jinhua's key locations, and has been affirmed by the Red Cross and related units. (Spike Pharmaceuticals)

2020

07-31

Jingmai Airport Test Flight Successfully Runway Cement Spike Manufacturing

On April 7, a Boeing 737-700 aircraft of China Eastern Airlines Yunnan took off from Kunming. After completing two flight test subjects, it landed safely at Lancang Jingmai Airport. This not only marked the basic completion of the airport flight area, The official start of the test flight also marked that the "Peak" brand airport runway cement passed the first "final exam". Lancang Jingmai Airport is a major project with milestone significance in the history of Pu'er transportation construction. Since then, an air corridor connecting southwest Yunnan and Southeast Asia has been added between Kunming and Pu'er, which will greatly promote the development and utilization of tourism resources in Lancang, Menglian and Ximeng "Pu'er Green Triangle" area, and promote the sustainable development of local economy and society; it is of great significance to strengthen the city's national defense construction, maintain border stability, promote national unity, improve emergency rescue capabilities, and promote Pu'er's integration into the country's "Belt and Road" construction. Since the start of the construction of the airport, Yunnan Jianfeng has been paying close attention to it, organizing technical research and repeated tests, and finally produced high-quality airport runway special cement, and with excellent product quality, superior product performance and high-quality service, it has become a runway for Lancang Airport. Cement manufacturer. This not only fills the gap of "peak" airport special cement, but also is of great significance to promote the "peak" brand and improve the market influence of enterprises. It is understood that Jingmai Airport is initially confirmed to be officially opened to traffic at the end of May. (Li Liangping)

2020

07-31

< 1...46 47 48...61 > 跳转到页